Abstract
Leishmaniasis is a protozoan zoonotic disease caused by the protozoa Leishmania with more than 24 species implicated in human disease. Leishmania spp. are transmitted by the Phlebotomus and Lutzomyia species of sand fly. Rates of leishmaniasis are increasing around the world, including in the United States. More recently leishmaniasis has been noted in the Southern United States, primarily in Texas with case reports of autochthonous transmission. Leishmaniasis has a varied clinical presentation ranging from localized cutaneous disease, mucocutaneous disease, to disseminated visceral disease. Treatment for leishmaniasis is complex and depends on the region of the world, the Leishmania spp. as well as the disease presentation. Vaccine development is critical for control and prevention efforts.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Petersen CA (2009) Leishmaniasis, an emerging disease found in companion animals in the United States. Top Companion Anim Med 24(4):182–188
Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366(9496):1561–1577
Beiter KJ, Wentlent ZJ, Hamouda AR, Thomas BN (2019) Nonconventional opponents: a review of malaria and leishmaniasis among United States armed forces. Peer J 7:e6313
Barry MA, Weatherhead JE, Hotez PJ, Woc-Colburn L (2013) Childhood parasitic infections endemic to the United States. Pediatr Clin North Am 60(2):471–485
José Antonio Ruiz-Postigo LGASJ (2020) Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators. WHO Weekly Surveill Rep 19:265–280
Wright NA, Davis LE, Aftergut KS, Parrish CA, Cockerell CJ (2008) Cutaneous leishmaniasis in Texas: a northern spread of endemic areas. J Am Acad Dermatol 58(4):650–652
Kipp EJ, Hergert M (2019) Endemic human cutaneous Leishmaniasis incidence in the United States. JAMA Dermatol 155(2):259–260
Kipp EJ, Mariscal J, Armijos RX, Weigel M, Waldrup K (2016) Genetic evidence of enzootic leishmaniasis in a stray canine and Texas mouse from sites in west and Central Texas. Mem Inst Oswaldo Cruz 111(10):652–654
González C, Wang O, Strutz SE, González-Salazar C, Sánchez-Cordero V, Sarkar S (2010) Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species. PLoS Negl Trop Dis 4(1):e585
Murray HW (2004) Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2(2):279–292
le Fichoux Y, Quaranta JF, Aufeuvre JP et al (1999) Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 37(6):1953–1957
Costa CH, Gomes RB, Silva MR et al (2000) Competence of the human host as a reservoir for Leishmania chagasi. J Infect Dis 182(3):997–1000
Barry MA, Bezek S, Serpa JA, Hotez PJ, Woc-Colburn L (2012) Neglected infections of poverty in Texas and the rest of the United States: management and treatment options. Clin Pharmacol Ther 92(2):170–181
Haque L, Villanueva M, Russo A et al (2018) A rare case of visceral leishmaniasis in an immunocompetent traveler returning to the United States from Europe. PLoS Negl Trop Dis 12(10):e0006727
Boggild AK, Ramos AP, Espinosa D et al (2010) Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg 83(2):345–350
Zijlstra EE, Ali MS, el-Hassan AM et al (1992) Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 86(5):505–507
Antinori S, Calattini S, Longhi E et al (2007) Clinical use of polymerase chain reaction performed on peripheral blood and bone marrow samples for the diagnosis and monitoring of visceral leishmaniasis in HIV-infected and HIV-uninfected patients: a single-center, 8-year experience in Italy and review of the literature. Clin Infect Dis 44(12):1602–1610
Aronson N, Herwaldt BL, Libman M et al (2016) Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 63(12):e202–e264
Davidson RN, di Martino L, Gradoni L et al (1996) Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 22(6):938–943
Davidson RN, Di Martino L, Gradoni L et al (1994) Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 87(2):75–81
Kim DH, Chung HJ, Bleys J (2009) Ghohestani RF. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl Trop Dis 3(2):e381
Jauréguiberry S, Graby G, Caumes E (2006) Efficacy of short-course intramuscular pentamidine isethionate treatment on Old World localized cutaneous leishmaniasis in 2 patients. Clin Infect Dis 42(12):1812–1813
Hellier I, Dereure O, Tournillac I et al (2000) Treatment of old world cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 200(2):120–123
McGwire BS, Satoskar AR (2014) Leishmaniasis: clinical syndromes and treatment. QJM 107(1):7–14
Vakil NH, Fujinami N, Shah PJ (2015) Pharmacotherapy for leishmaniasis in the United States: focus on miltefosine. Pharmacotherapy 35(5):536–545
Sundar S, Jha TK, Thakur CP et al (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347(22):1739–1746
Soto J, Arana BA, Toledo J et al (2004) Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 38(9):1266–1272
Machado PR, Ampuero J, Guimarães LH et al (2010) Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4(12):e912
Stockdale L, Newton R (2013) A review of preventative methods against human Leishmaniasis infection. PLoS Negl Trop Dis 7:e2278. https://doi.org/10.1371/journal.pntd.0002278
González UAJ (2015) Vector and reservoir control for preventing leishmaniasis (review). Cochrane Database Syst Rev 2015(8):CD008736. https://doi.org/10.1002/14651858.CD008736.pub2
Wilson Id AL, Courtenay O, Kelly-Hope LA et al (2020) The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis 14(1):e0007831. https://doi.org/10.1371/journal.pntd.0007831
Otranto D, Dantas-Torres F (2013) The prevention of canine leishmaniasis and its impact on public health. Trends Parasitol 29:339–345
Yimam Y, Mohebali M (2020) Effectiveness of insecticide-impregnated dog collars in reducing incidence rate of canine visceral leishmaniasis: a systematic review and meta-analysis. PLoS One 15:e0238601. https://doi.org/10.1371/journal.pone.0238601
Palatnik-de-Sousa CB, Nico D (2020) The delay in the licensing of protozoal vaccines: a comparative history. Front Immunol 11:204
Evans KJ, Kedzierski L (2012) Development of vaccines against visceral Leishmaniasis. J Trop Med 2012:14. https://doi.org/10.1155/2012/892817
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bhamidipati, D., Woc-Colburn, L. (2021). Leishmaniasis. In: Weatherhead, J.E. (eds) Neglected Tropical Diseases - North America. Neglected Tropical Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-63384-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-030-63384-4_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-63383-7
Online ISBN: 978-3-030-63384-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)